Healthcare Services Australia

Australia Biologics CDMO Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Australia Biologics CDMO Market Industry Trends and Forecast to 2034: Segmented by (Product, Service, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $281.3 Mn Placeholder estimate
Estimate 2025 $316.7 Mn 1.2% of the global market
Projected 2034 $921.5 Mn 191% Adds $604.8 Mn over 9 forecast years
CAGR 2025–2034 12.6% Faster than 69% of 107 Healthcare Services markets here
Key players 6 +1
  • Australia is 1.17% of the global market.
  • In APAC, the largest is China at $2.33 Bn.
  • Fastest growing: India at 13.8% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$604.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Biologics CDMO Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $281.3 Mn — —
2025 (base) $316.7 Mn +$35.4 Mn —
2026 (forecast) $356.6 Mn +$39.9 Mn +12.6%
2027 (forecast) $401.6 Mn +$44.9 Mn +26.8%
2028 (forecast) $452.2 Mn +$50.6 Mn +42.8%
2029 (forecast) $509.1 Mn +$57.0 Mn +60.8%
2030 (forecast) $573.3 Mn +$64.1 Mn +81%
2031 (forecast) $645.5 Mn +$72.2 Mn +103.8%
2032 (forecast) $726.8 Mn +$81.3 Mn +129.5%
2033 (forecast) $818.4 Mn +$91.6 Mn +158.4%
2034 (forecast) $921.5 Mn +$103.1 Mn +191%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Biologics CDMO Market Analysis at a glance
Market size, 2025$316.7 Mn placeholder estimate
Forecast, 2034$921.5 Mn placeholder estimate
Growth (CAGR), 2025–203412.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledBiologics Contract Development and Manufacturing (CDMO)
SegmentsProduct, service and end user (see all)
Key playersLonza Ltd, Samsung Biologics, WuXi Biologics, FUJIFILM Holdings Corporation, Catalent and 1 more (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Biologics CDMO Market Analysis Executive Summary

Biologics CDMOs develop and manufacture antibodies, proteins and vaccines for pharma and biotech companies.

Key segments of the biologics CDMO market include product (Monoclonal Antibodies, Recombinant Proteins and Vaccines) and service (Process Development, Clinical Manufacturing and Commercial Manufacturing).

Bar chart: Australia Biologics CDMO market size, 2024–2034, placeholder estimates. $281.3 Mn in 2024, $316.7 Mn in 2025 and $921.5 Mn in 2034, 12.6% CAGR.
Australia Biologics CDMO market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Biologics CDMO Market Dynamics

Market Growth Drivers

Growing drug pipelines, more complex biologics, cost pressure on drug makers and the need for speed are driving the biologics CDMO market. Many companies now outsource work they used to do in-house.

Opportunity

Advanced therapies, AI-driven operations and expansion in India, China and Southeast Asia give the biologics CDMO market room to grow.

Market Restraints

Capacity shortages, strict quality rules, data security concerns and pricing pressure hold back the biologics CDMO market.

Competitive Landscape for Biologics CDMO Market in Australia

The biologics CDMO market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Biologics CDMO Market in Australia

Biologics CDMO in Australia: payment

Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[1]

[1] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Licensing, quality standards and payment models from public and private payers shape how biologics CDMO services are delivered and paid for in Australia. Government health programs and insurance coverage are key to access.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Biologics CDMO right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Biologics CDMO in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 4th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Biologics CDMO market in Australia?
Placeholder estimate: about $316.7 Mn in 2025, rising to about $921.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Biologics CDMO market in Australia growing?
Placeholder estimate: about 12.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Biologics CDMO market report cover?
The report splits the market by product (Monoclonal Antibodies, Recombinant Proteins, Vaccines, ADCs), service (Process Development, Clinical Manufacturing, Commercial Manufacturing, Fill-Finish) and end user (Hospitals, Clinics, Home Care, Corporate and Payer Clients).
Who are the key players in the Biologics CDMO market?
Key players include Lonza Ltd, Samsung Biologics, WuXi Biologics, FUJIFILM Holdings Corporation, Catalent and AGC Biologics.
What is driving the Biologics CDMO market?
Growing drug pipelines, more complex biologics, cost pressure on drug makers and the need for speed are driving the biologics CDMO market. Many companies now outsource work they used to do in-house.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
Back to Catalogue

Related Healthcare Services reports in Australia

See all

Related on drug development and manufacturing and biologics and biosimilars

See the topic